400 - Mamasteam: bevacizumab (BVZ) in the treatment of breast cancer in advanced lines of treatment, a new model for the assessment of activity in advance...

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Cytotoxic agents
Breast Cancer
Biological therapy
Presenter Juan De La Haba Rodriguez
Authors J. De La Haba Rodriguez1, A. Gonzalez Martin2, A. Rodriguez-Lescure3, G. Pulido4, A. Sanchez-MuÑoz5, R. Marquez2, M. Guirado Rueño6, D. Torrejon Castro7, E. Alba-Conejo5, J. Cortes Castan8
  • 1Medical Oncology, Reina Sofía Hospital. Biomedical Research Institute (IMIBIC), 14005 - Cordoba/ES
  • 2Servicio De Oncologia Medica, MD Anderson Cancer Center Espana, ES-28033 - Madrid/ES
  • 3Medical Oncology, Hospital Universitario de Elche, Elche/ES
  • 4Medical Oncology, University Reina Sofia Hospital, Cordoba/ES
  • 6Medical Oncology, Hospital universitario de Elche, Elche/ES
  • 7Oncologia, Vall d'Hebron University HospitalInstitut d'Oncologia, ES-08035 - Barcelona/ES
  • 8Oncologia, Vall d`Hebron University Hospital Institut d'Oncologia, 08035 - Barcelona/ES



Bevacizumab is the first anti-angiogenic approved in the first-line treatment in advanced breast cancer. However, little is known about his activity in advanced lines. In the treatment of metastatic cancer, the response rate and time to progression decreases as we move forward in subsequent therapeutic lines [1]. Objective: To compare in each patient and in a paired way BVZ activity in advanced lines of treatment, achieved with the previous treatment.


Coming of 5 Spanish hospitals have been selected 129 consecutive patients who received treatment with BVZ second-line treatment or later. For the efficacy analysis were used tests of Wilcoxon signed-rank and sign test.


When analyzing the data of 114 patients (88.4%) had progressed. The responses obtained with the previous line of treatment (without BVZ) were: RC: 4 (3.1%), RP: 31 (24%), EE: 54 (41.9%), PROG: 36 (27.9 %) and NV: 4 (3.1%). The line obtained during treatment with BVZ: RC: 2 (1.6%), RP 31 (44.2%), EE: 37 (28.7%), PROG: 28 (21.7%) and NV: 5 (3.9%). With respect to time to progression (TP), 76 patients achieved a TP longer than they had achieved with the previous line of treatment (p = 0.011). The overall median time to progression was also higher: 4.06 vs 5.83 months (p = 0.032).


Opposite to it is expected, treatment with bevacizumab in advanced linesimproves the results obtained with previous treatment lines. This suggests that bevacizumab is active in advanced lines and produces favorable changes in the natural history of patients with metastatic breast carcinoma 1. Dufresne, A. et al. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat, 2008. 107(2): p. 275-9.


All authors have declared no conflicts of interest.